



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Wednesday, November 25, 2009

Gen-Probe Life Sciences Ltd

[View the current Gen-Probe Life Sciences Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/30916-Gen-Probe+Life+Sciences+Ltd.html)

(<http://www.bioportfolio.com/biocorporate/30916-Gen-Probe+Life+Sciences+Ltd.html>)

Contact Details:

**Heron House, Oaks Business Park, Crewe Road,
Wythenshawe
Manchester
M23 9HZ
United Kingdom**

Tel: 44 (0)161 946 2200

Fax: 44 (0)161 946 2211

Email: pharmaservices@gen-probe.com

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. NATs harness the power of biotechnology to detect diseases more rapidly and/or accurately than older testing methods, and have therefore become one of the fastest-growing segments of the in vitro diagnostics industry.

Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases (STDs), tuberculosis, strep throat, pneumonia and fungal infections. Gen-Probe's key clinical diagnostics products include the APTIMA COMBO 2® and PACE® assays, which are used to detect the common STDs Chlamydia and gonorrhea.

In blood screening, Gen-Probe developed and manufactures the PROCLEIX® assay, which is used to detect HIV-1 and the hepatitis C virus (HCV) in donated human blood; the PROCLEIX ULTRIO® assay, which detects the hepatitis B virus in addition to HIV-1 and HCV; and the PROCLEIX WNV (West Nile virus) assay. Gen-Probe's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics, Inc.

Gen-Probe also has a robust development pipeline. For example, the Company is developing NATs to detect prostate cancer, drug-resistant hospital infections, and human papillomavirus, which causes cervical cancer. In addition, Gen-Probe is working with General Electric and Millipore to develop NATs that detect microorganisms that commonly contaminate industrial processes.

Several of Gen-Probe's current and future molecular diagnostic tests can be performed on the Company's TIGRIS® instrument, the only fully automated, high-throughput NAT system for diagnostics and blood screening.

Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.

Press Releases on Gen-Probe Life Sciences Ltd:

Prodesse&apos;s ProParaflu+(TM) Assay Cleared for US Marketing by FDA	24th November, 2009	Gen-Probe Incorporated	<i>Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated</i>
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform	24th November, 2009	Bioniche Life Sciences Inc.	<i>-Japanese patent issuances facilitate commercialization of MCC in Japan- BELLEVILLE, ON, Nov. 24 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/ --</i>
Sigma-Aldrich to Present at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009	24th November, 2009	Sigma-Aldrich Corporation	<i>Sigma-Aldrich Corporation (Nasdaq: SIAL) will be presenting at the NASDAQ OMX conference on Tuesday, December 1st at 1:45 PM GMT in London, 7:45 AM US/CST. WASHINGTON, Nov. 24 /PRNewswire/ --</i>
Union Labor Life & VSP Vision Care Align to Offer Vision Insurance Products	24th November, 2009	ULLICO Inc.	<i>The Union Labor Life Insurance Company ("Union Labor Life") announced today that it has aligned with VSP (Â®),()the nation&apos;s largest vision benefits NEW YORK, Nov. 24 /PRNewswire/ --</i>
Guardian to Continue Following Its Current Coverage Guidelines for Mammography Screenings	24th November, 2009	The Guardian Life Insurance Company of America	<i>The Guardian Life Insurance Company of America (Guardian), one of the largest mutual life insurers and a leading provider of employee benefits for small and mid-sized</i>

BioNews Results for Gen-Probe Life Sciences Ltd



- [Registration Deadline Extended for the California Healthcare Policy Forum](#)
Yahoo! Canada: Oct 27 2009 12:30AM Matching: gen probe life sciences

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

